Clinical trial · Observational
Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer
Intravenous Chemotherapy Versus Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer
NCT06535334CI-TRIAL-00079406unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to compare intravenous chemotherapy versus intraperitoneal chemotherapy in patients with recurrent ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Intravenous Chemotherapy Versus Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- intravenous chemotherapy
- description
- triweekly chemotherapy with carboplatin AUC=5\~6 + liposomal-doxorubicin 30\~40mg/m2 or paclitaxel 175mg/m2 0r docetaxel 60\~75mg/m2
- interventionNames
- Drug: Chemotherapy
- label
- intraperitoneal chemotherapy
- description
- Day 1 IV Paclitaxel 135 mg/m2 + IP Cisplatin 75-100 mg/m2 or IP carboplatin (AUC = 6) Day 8 IP Paclitaxel 60 mg/m2 Every 21 days \* 6 cycles OR Day 1 IP Carboplatin AUC=5 or IP Cisplatin 50-75mg/m2 Day 2 IV Liposomal doxorubicin 15 mg/m2 + IP Liposomal doxorubicin 15 mg/m2 Every 28 days \* 6 cycles
- interventionNames
- Drug: Chemotherapy
Primary outcomes (2)
- measure
- RFS
- timeFrame
- the time interval from the date of surgery or the start of chemotherapy to clinically defined recurrence, disease progression, death from any cause or last follow-up
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * women who had recurrent ovarian cancer and was treated with either intravenous or intraperitoneal platinum based chemotherapy Exclusion Criteria: * women who did not complete the designated treatment course (exception to those who had to quit due to progressive disease or death of any cause)
References
Publications (0)
Data not yet available
No reference posted for this study.